S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:SLNO

Soleno Therapeutics - SLNO Stock Forecast, Price & News

$2.59
-0.27 (-9.44%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.36
▼
$2.92
50-Day Range
$0.89
▼
$2.91
52-Week Range
$0.85
▼
$6.30
Volume
229,218 shs
Average Volume
160,491 shs
Market Capitalization
$21.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Soleno Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
208.9% Upside
$8.00 Price Target
Short Interest
Healthy
5.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.47) to ($1.99) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

777th out of 1,025 stocks

Electromedical Equipment Industry

19th out of 24 stocks

See Top Rated MarketRank™ Stocks Here
SLNO stock logo

About Soleno Therapeutics (NASDAQ:SLNO) Stock

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The firm focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Stock News Headlines

January 30, 2023 | markets.businessinsider.com
Oppenheimer Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)
January 29, 2023 | reuters.com
SLNO.OQ - | Stock Price & Latest News | Reuters
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 26, 2023 | finance.yahoo.com
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
December 20, 2022 | msn.com
Peering Into Soleno Therapeutics's Recent Short Interest
December 19, 2022 | marketwatch.com
Soleno Therapeutics Shares Double After Financing Commitment
December 19, 2022 | markets.businessinsider.com
Why Is Soleno Therapeutics (SLNO) Stock Up 130% Today?
December 19, 2022 | marketwatch.com
Thinking about buying stock in Mullen Automotive, Soleno Therapeutics, Agrify, AMC Entertainment, or Amyris?
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 19, 2022 | finance.yahoo.com
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
November 9, 2022 | finance.yahoo.com
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
October 3, 2022 | finance.yahoo.com
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
September 22, 2022 | finance.yahoo.com
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
September 7, 2022 | finance.yahoo.com
Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds
September 6, 2022 | finance.yahoo.com
Soleno Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 21, 2022 | reuters.com
Soleno Therapeutics Inc
July 20, 2022 | finance.yahoo.com
Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful
July 20, 2022 | finance.yahoo.com
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
July 11, 2022 | finance.yahoo.com
Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference
July 6, 2022 | finance.yahoo.com
4 Small Stocks to Bet on in an Upbeat Drugs Industry
June 14, 2022 | finance.yahoo.com
Why Soleno Therapeutics Shares Are Surging Today
June 13, 2022 | seekingalpha.com
Soleno Therapeutics surges on positive data from Prader-Willi syndrome treatment
June 13, 2022 | finance.yahoo.com
Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS
June 7, 2022 | finance.yahoo.com
Soleno Therapeutics Announces Presentations at ENDO 2022
May 19, 2022 | finance.yahoo.com
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
May 17, 2022 | finance.yahoo.com
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 2, 2022 | finance.yahoo.com
Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
See More Headlines
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Company Calendar

Last Earnings
11/09/2022
Today
2/05/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLNO
CUSIP
N/A
CIK
1484565
Web
www.soleno.life
Phone
(650) 213-8444
Fax
650-213-8383
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+208.9%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.3088)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,910,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-124.06%
Return on Assets
-67.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.80
Quick Ratio
2.80

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.34 per share
Price / Book
0.78

Miscellaneous

Outstanding Shares
8,160,000
Free Float
5,809,000
Market Cap
$21.13 million
Optionable
Not Optionable
Beta
0.12

Key Executives

  • Anish Bhatnagar
    President, Chief Executive Officer & Director
  • James H. MackanessJames H. Mackaness
    Chief Financial Officer
  • Kristen Yen
    Vice President-Clinical Operations
  • Michael Woloschak
    Vice President-Clinical Development
  • Harish Ravivarapu
    Vice President-Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SLNO Stock - Frequently Asked Questions

What is Soleno Therapeutics' stock price forecast for 2023?

0 Wall Street analysts have issued 12 month target prices for Soleno Therapeutics' stock. Their SLNO share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 208.9% from the stock's current price.
View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts.

How have SLNO shares performed in 2023?

Soleno Therapeutics' stock was trading at $1.98 on January 1st, 2023. Since then, SLNO stock has increased by 30.8% and is now trading at $2.59.
View the best growth stocks for 2023 here.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a decrease in short interest in January. As of January 15th, there was short interest totaling 265,400 shares, a decrease of 55.1% from the December 31st total of 590,900 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 6.0% of the shares of the company are sold short.
View Soleno Therapeutics' Short Interest.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our SLNO earnings forecast.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.29.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics shares reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness and William G Harris.
View institutional ownership trends.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $2.59.

How much money does Soleno Therapeutics make?

Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $21.13 million. The company earns $-30,910,000.00 in net income (profit) each year or ($3.3088) on an earnings per share basis.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.

This page (NASDAQ:SLNO) was last updated on 2/5/2023 by MarketBeat.com Staff